These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22 related articles for article (PubMed ID: 21355602)

  • 1. Ramatroban-Based Analogues Containing Fluorine Group as Potential
    Huang LA; Huang KX; Tu J; Kandeel F; Li J
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.
    Kindon N; Andrews G; Baxter A; Cheshire D; Hemsley P; Johnson T; Liu YZ; McGinnity D; McHale M; Mete A; Reuberson J; Roberts B; Steele J; Teobald B; Unitt J; Vaughan D; Walters I; Stocks MJ
    ACS Med Chem Lett; 2017 Sep; 8(9):981-986. PubMed ID: 28947948
    [No Abstract]   [Full Text] [Related]  

  • 3. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
    Sykes DA; Bradley ME; Riddy DM; Willard E; Reilly J; Miah A; Bauer C; Watson SJ; Sandham DA; Dubois G; Charlton SJ
    Mol Pharmacol; 2016 May; 89(5):593-605. PubMed ID: 26916831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.
    Luker T; Bonnert R; Schmidt J; Sargent C; Paine SW; Thom S; Pairaudeau G; Patel A; Mohammed R; Akam E; Dougall I; Davis AM; Abbott P; Brough S; Millichip I; McInally T
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3616-21. PubMed ID: 21592791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of CRTh2 antagonist LAS191859: Long receptor residence time translates into long-lasting in vivo efficacy.
    Calbet M; Andrés M; Armengol C; Bravo M; Eichhorn P; López R; García-González V; Roberts R; Miralpeix M
    Pharmacol Res; 2016 Sep; 111():208-216. PubMed ID: 27317944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta12-prostaglandin D2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes.
    Gazi L; Gyles S; Rose J; Lees S; Allan C; Xue L; Jassal R; Speight G; Gamble V; Pettipher R
    Prostaglandins Other Lipid Mediat; 2005 Jan; 75(1-4):153-67. PubMed ID: 15789622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.
    Mimura H; Ikemura T; Kotera O; Sawada M; Tashiro S; Fuse E; Ueno K; Manabe H; Ohshima E; Karasawa A; Miyaji H
    J Pharmacol Exp Ther; 2005 Jul; 314(1):244-51. PubMed ID: 15798001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of the prostaglandin D2 receptor CRTH2.
    Pettipher R; Hansel TT
    Drug News Perspect; 2008; 21(6):317-22. PubMed ID: 18836589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils.
    Townley RG; Agrawal S
    Ann Allergy Asthma Immunol; 2012 Dec; 109(6):365-74. PubMed ID: 23176872
    [No Abstract]   [Full Text] [Related]  

  • 10. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases.
    Schuligoi R; Sturm E; Luschnig P; Konya V; Philipose S; Sedej M; Waldhoer M; Peskar BA; Heinemann A
    Pharmacology; 2010; 85(6):372-82. PubMed ID: 20559016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zwitterionic CRTh2 antagonists.
    Luker T; Bonnert R; Paine SW; Schmidt J; Sargent C; Cook AR; Cook A; Gardiner P; Hill S; Weyman-Jones C; Patel A; Thom S; Thorne P
    J Med Chem; 2011 Mar; 54(6):1779-88. PubMed ID: 21355602
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.